Research updates, December 10

Written by

  • A new study of nearly 10,000 people with Long COVID confirms what many with the disease already know: Long COVID can cause severe financial burden. Published in Health Services Research, researchers analyzed the results of a survey that assessed food insecurity, inability to pay bills, and threat of losing utility service. They found that the disease affected all socioeconomic statuses, but people who already had low incomes prior to developing Long COVID were worst off. “People’s financial well-being is being affected by Long COVID,” one of the study’s authors said in a press release. “That’s something we should care about.”
     
  • A new monoclonal antibody clinical trial will launch this winter, according to Long COVID and ME researcher Dr. Nancy Klimas. Researchers will test AstraZeneca’s Evusheld 2.0, also known as Sipavibart. Klimas said the 100-person randomized controlled trial should launch in early 2025. The trial is funded by the state of Florida and the Schmidt Initiative for Long COVID. Watch the interview in which the trial was announced on a recent episode of the podcast, Long COVID the Answers.
     
  • Mount Sinai’s Cohen Center for Recovery from Complex Chronic Illnesses (CoRE) is looking for volunteers for a six month clinical trial for Long COVID to test two HIV drugs. The antiviral trial, based in New York City, will include three patient groups: Truvada, Selezentry (Maraviroc), and a placebo. It requires four in-person visits, blood and saliva samples, and online questionnaires. To see if you are eligible to enroll, or for more information, contact coreresearch@mountsinai.org.

More original Long COVID articles like this one, delivered to your inbox once a week

* indicates required

View previous campaigns

One response

Leave a Reply

Your email address will not be published. Required fields are marked *

get the latest long covid news

Processing…
Success! You're on the list.
SpotifyApple PodcastsPocketCastsAmazon MusiciHeartRadio